Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Nursepoop2 who wrote (52781)	2/9/2005 7:51:26 AM
From: DanZ	Respond to of 53068

Howdy, Nurse... Welcome to the thread. I never owned DRMD, and remain cautious on MTXX until the outcome of the product liability lawsuits becomes clearer. It is my understanding that a case in Los Angeles will be the first to go to trial. Go to lasuperiorcourt.org and type in case number YC048136. It looks like the trial will start on March 28, 2005. While I firmly believe that nothing supports the assertion that Zicam Cold Remedy causes Anosmia, I could be wrong, and one never knows how a jury will view a case even when the evidence doesn't support their conclusion. I hold a position in MTXX, but it is small compared to what I once had. If Matrixx prevails in the first case, the stock should work its way to the upper teens to low 20s where it is certainly fairly valued based on the company's earnings growth exclusive of the potential risk of the product liability claims. I like the 2x Rydex funds for their leverage, but don't like the fact that I can only trade them at the close. Best of luck with your trades, and make sure that you wash your hands after handling the patients! lol Dan